Webinar | The Native Antigen Company – Exit for Mercia EIS Fund

Mercia’s EIS fund principal Peter Dines discusses with Dr. Paul Mattick the recent sale of a portfolio company for 8x cost of investment. The pair also discussed: – The Mercia groups investment model – Our EIS is a venture capital investment with downside protection – This exit illustrates the potential when investing with Mercia

30th July 2020
1 minute read

Mercia’s EIS fund principal Peter Dines discusses with Dr. Paul Mattick the recent sale of a portfolio company for 8x cost of investment.

The pair also discussed:

– The Mercia groups investment model
– Our EIS is a venture capital investment with downside protection
– This exit illustrates the potential when investing with Mercia

Let’s start the conversation

Whether you’re actively exploring investment or just starting to think about what comes next, we’re always happy to talk. Conversations come first – there’s no pressure and no obligation.

Start the conversation

Webinar | The Native Antigen Company – Exit for Mercia EIS Fund

Let’s start the conversation

Mercia Ventures

For founders

Insights